Xconomy -- David Urdal, the scientific entrepreneur who co-founded the modern version of Dendreon over 15 years ago and helped turn it into a pioneer of cancer immunotherapy, is stepping down from his job as chief scientific officer at the Seattle biotech company (NASDAQ: DNDN).
